$262 Million is the total value of SENZAR ASSET MANAGEMENT, LLC's 52 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDadr | $25,739,000 | +10.6% | 490,996 | +11.5% | 9.83% | -20.2% |
| SNY | Buy | SANOFIsponsored adr | $25,447,000 | +7.5% | 478,600 | +5.7% | 9.72% | -22.4% |
| CYH | Buy | COMMUNITY HEALTH SYS INC NEW | $19,119,000 | +23.1% | 421,400 | +6.3% | 7.30% | -11.2% |
| ABBV | Sell | ABBVIE INC | $17,474,000 | -28.2% | 309,595 | -34.6% | 6.67% | -48.2% |
| INSM | New | INSMED INC | $16,358,000 | – | 818,700 | +100.0% | 6.25% | – |
| QCOR | New | QUESTCOR PHARMACEUTICALS INC | $14,622,000 | – | 158,100 | +100.0% | 5.58% | – |
| OFIX | Sell | ORTHOFIX INTL N V | $14,170,000 | -5.8% | 390,898 | -21.7% | 5.41% | -32.1% |
| AMGN | Sell | AMGEN INC | $14,121,000 | -10.6% | 119,298 | -6.9% | 5.39% | -35.5% |
| MDVN | Sell | MEDIVATION INC | $12,859,000 | -20.4% | 166,834 | -33.6% | 4.91% | -42.6% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $10,988,000 | +94.7% | 255,128 | +80.8% | 4.20% | +40.4% |
| MYL | New | MYLAN INC | $9,832,000 | – | 190,700 | +100.0% | 3.76% | – |
| MDT | New | MEDTRONIC INC | $9,379,000 | – | 147,100 | +100.0% | 3.58% | – |
| AGN | Sell | ALLERGAN INC | $8,782,000 | -29.1% | 51,900 | -48.0% | 3.35% | -48.9% |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $8,615,000 | – | 161,100 | +100.0% | 3.29% | – |
| MGLN | Buy | MAGELLAN HEALTH INC | $6,735,000 | +9.8% | 108,200 | +4.6% | 2.57% | -20.8% |
| CAH | Buy | CARDINAL HEALTH INC | $6,562,000 | +5.2% | 95,700 | +7.4% | 2.51% | -24.1% |
| WCG | Sell | WELLCARE HEALTH PLANS INC | $5,906,000 | +4.3% | 79,100 | -11.2% | 2.26% | -24.7% |
| XNPT | Buy | XENOPORT INC | $5,664,000 | +39.1% | 1,172,700 | +48.9% | 2.16% | +0.3% |
| KYTH | Buy | KYTHERA BIOPHARMACEUTICALS I | $4,792,000 | +34.7% | 124,900 | +39.6% | 1.83% | -2.9% |
| SGNT | Buy | SAGENT PHARMACEUTICALS INC | $4,735,000 | +49.7% | 183,100 | +35.2% | 1.81% | +7.9% |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $4,649,000 | – | 384,900 | +100.0% | 1.78% | – |
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $4,074,000 | +325.3% | 262,000 | +438.0% | 1.56% | +206.9% |
| CORI | New | CORIUM INTL INC | $3,975,000 | – | 511,500 | +100.0% | 1.52% | – |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $3,352,000 | +104.9% | 923,200 | +119.1% | 1.28% | +47.8% |
| ACRX | New | ACELRX PHARMACEUTICALS INC | $2,005,000 | – | 195,600 | +100.0% | 0.77% | – |
| RTRX | New | RETROPHIN INC | $1,856,000 | – | 158,100 | +100.0% | 0.71% | – |
| BIIB | Exit | BIOGEN IDEC INC | $0 | – | -18,200 | -100.0% | -2.95% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CONCERT PHARMACEUTICALS INC | 16 | Q2 2018 | 4.5% |
| SANOFI | 14 | Q2 2018 | 17.6% |
| CORIUM INTL INC | 14 | Q3 2017 | 2.3% |
| FOAMIX PHARMACEUTICALS LTD | 14 | Q2 2018 | 2.1% |
| RETROPHIN INC | 13 | Q2 2017 | 3.0% |
| ALDER BIOPHARMACEUTICALS INC | 12 | Q2 2018 | 3.9% |
| RIGEL PHARMACEUTICALS INC | 12 | Q3 2016 | 1.8% |
| INSMED INC | 11 | Q3 2017 | 6.2% |
| TEVA PHARMACEUTICAL INDS LTD | 10 | Q1 2016 | 12.3% |
| ORTHOFIX INTL N V | 10 | Q1 2017 | 9.0% |
View SENZAR ASSET MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corium International, Inc.Sold out | February 14, 2018 | 0 | 0.0% |
| Aviragen Therapeutics, Inc. | February 13, 2017 | 1,774,876 | 4.6% |
| CONCERT PHARMACEUTICALS, INC. | February 13, 2017 | 400,588 | 1.8% |
| Foamix Pharmaceuticals Ltd. | February 13, 2017 | 550,997 | 1.5% |
| NEVRO CORPSold out | February 13, 2017 | 0 | 0.0% |
| TIVITY HEALTH, INC. | February 13, 2017 | 383,200 | 1.0% |
| HEALTHWAYS, INC | February 12, 2016 | 2,525,044 | 7.0% |
| Sientra, Inc. | February 12, 2016 | 580,851 | 3.2% |
| Biota Pharmaceuticals, Inc. | January 15, 2016 | 2,025,976 | 5.2% |
View SENZAR ASSET MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-10-31 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| SC 13G/A | 2018-02-14 |
| 13F-HR | 2018-02-13 |
| 13F-HR | 2017-11-13 |
| 13F-HR | 2017-08-11 |
| 13F-HR | 2017-05-12 |
| 13F-HR | 2017-02-14 |
| SC 13G/A | 2017-02-13 |
View SENZAR ASSET MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.